dc.contributor
Institut Català de la Salut
dc.contributor
[van de Haar J] Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam. [Roepman P] Medical Department, Hartwig Medical Foundation, Amsterdam, The Netherlands. [Andre F] INSERM U981, Gustave Roussy, Villejuif. Department of Cancer Medicine, Gustave Roussy, Villejuif. Faculty of Medicine, Université Paris-Saclay, Kremlin Bicêtre, France. [Balmaña J, Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Castro E] Department of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain. [Chakravarty D] Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. [Dienstmann R] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. University of Vic—Central University of Catalonia, Vic, Spain. Oncoclínicas, São Paulo, Brazil
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
van de Haar, Joris
dc.contributor.author
Roepman, Paul
dc.contributor.author
andre, fabrice
dc.contributor.author
Castro, Elena
dc.contributor.author
Chakravarty, Debyani
dc.contributor.author
Balmaña, Judith
dc.contributor.author
Dienstmann, Rodrigo
dc.contributor.author
Mateo, Joaquin
dc.date.accessioned
2025-10-25T05:38:56Z
dc.date.available
2025-10-25T05:38:56Z
dc.date.issued
2024-10-31T07:34:46Z
dc.date.issued
2024-10-31T07:34:46Z
dc.identifier
van de Haar J, Roepman P, Andre F, Balmaña J, Castro E, Chakravarty D, et al. ESMO Recommendations on clinical reporting of genomic test results for solid cancers. Ann Oncol. 2024 Nov;35(11):954–67.
dc.identifier
https://hdl.handle.net/11351/12161
dc.identifier
10.1016/j.annonc.2024.06.018
dc.identifier.uri
http://hdl.handle.net/11351/12161
dc.description.abstract
Genomics; Next-generation sequencing; Targeted therapies
dc.description.abstract
Genómica; Secuenciación de nueva generación; Terapias dirigidas
dc.description.abstract
Genòmica; Seqüenciació de nova generació; Teràpies dirigides
dc.description.abstract
Background
Genomic tumour profiling has a crucial role in the management of patients with solid cancers, as it helps selecting and prioritising therapeutic interventions based on prognostic and predictive biomarkers, as well as identifying markers of hereditary cancers. Harmonised approaches to interpret the results of genomic testing are needed to support physicians in their decision making, prevent inequalities in precision medicine and maximise patient benefit from available cancer management options.
Methods
The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group assembled a group of international experts to propose recommendations for preparing clinical genomic reports for solid cancers. These recommendations aim to foster best practices in integrating genomic testing within clinical settings. After review of available evidence, several rounds of surveys and focused discussions were conducted to reach consensus on the recommendation statements. Only consensus recommendations were reported. Recommendation statements were graded in two tiers based on their clinical importance: level A (required to maintain common standards in reporting) and level B (optional but necessary to achieve ideal practice).
Results
Genomics reports should present key information in a front page(s) followed by supplementary information in one or more appendices. Reports should be structured into sections: (i) patient and sample details; (ii) assay and data analysis characteristics; (iii) sample-specific assay performance and quality control; (iv) genomic alterations and their functional annotation; (v) clinical actionability assessment and matching to potential therapy indications; and (vi) summary of the main findings. Specific recommendations to prepare each of these sections are made.
Conclusions
We present a set of recommendations aimed at structuring genomics reports to enhance physician comprehension of genomic profiling results for solid cancers. Communication between ordering physicians and professionals reporting genomic data is key to minimise uncertainties and to optimise the impact of genomic tests in patient care.
dc.description.abstract
This project was funded by the European Society for Medical Oncology (no grant number is applicable).
dc.format
application/pdf
dc.relation
Annals of Oncology;35(11)
dc.relation
https://doi.org/10.1016/j.annonc.2024.06.018
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Medicina personalitzada
dc.subject
Càncer - Teràpia genètica
dc.subject
Medicina--Societats, etc.
dc.subject
DISEASES::Neoplasms
dc.subject
Other subheadings::Other subheadings::/therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Genetic Testing
dc.subject
HEALTH CARE::Health Care Economics and Organizations::Organizations::Societies::Societies, Medical
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Precision Medicine
dc.subject
ENFERMEDADES::neoplasias
dc.subject
Otros calificadores::Otros calificadores::/terapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::pruebas genéticas
dc.subject
ATENCIÓN DE SALUD::economía y organizaciones para la atención de la salud::organizaciones::sociedades::sociedades médicas
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::medicina de precisión
dc.title
ESMO Recommendations on clinical reporting of genomic test results for solid cancers
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion